Huberman is the most quoted voice in peptides and the most selectively quoted. A faithful summary of his two Huberman Lab episodes: the mechanisms he finds credible, the compounds he tells listeners to avoid, and the sourcing advice that almost never survives the clip.
Search for almost any peptide and you will find a clip of Andrew Huberman, PhD, professor of neurobiology and ophthalmology at Stanford School of Medicine, saying something encouraging about it. What you will rarely find is the ninety seconds either side of that clip, which is usually where the caution lives.
Huberman has covered peptides at length twice on the Huberman Lab podcast:
| Episode | Date | Format |
|---|---|---|
| Benefits & Risks of Peptide Therapeutics for Physical & Mental Health | 1 April 2024 | Solo |
| Dr. Craig Koniver: Peptide & Hormone Therapies for Health, Performance & Longevity | 7 October 2024 | Guest, Craig Koniver, MD |
Note the title of the first one. Benefits and risks. The risks half runs roughly as long as the benefits half, and it is the half that gets edited out.
This is a summary of his stated positions, with links so you can check every one against the source. It is not an endorsement of anything by him, and he has no connection to this site or to any product on it.
The organising idea of the solo episode is pleiotropy — the fact that one molecule does many things at once. Huberman's position is that peptide effects are rarely, if ever, narrow and specific. A compound that stimulates tissue growth where you want it stimulates tissue growth generally, because the receptors it acts on are not confined to the injury.
Everything else he says follows from this. It is why he treats "it healed my shoulder" and "it may accelerate something you do not know you have" as the same claim viewed from two angles, rather than as a benefit and an unrelated risk.
This is the compound he is most often clipped about, usually for the anecdote: he described developing an L5 disc issue from deadlifting, and reported that his persistent back pain resolved after a small number of injections.
Mechanism as he describes it: BPC-157 upregulates vascular endothelial growth factor (VEGF), driving angiogenesis — the growth of new blood vessels — at the site of injury, alongside fibroblast migration and cell turnover. New blood supply to damaged tissue is a plausible route to faster repair.
The caution attached to that same mechanism: angiogenesis is not selective. A tumour needs a blood supply to grow, and promoting vascularisation systemically could in principle feed one you do not know about. Huberman makes the point by inverting it: an entire class of oncology drugs, bevacizumab (Avastin) among them, works by *inhibiting* VEGF. He advises people with any cancer concern to avoid it.
He is also explicit that the human evidence is thin. The data behind BPC-157 is overwhelmingly animal work plus what he calls anecdata — self-reports, at volume, which is a different thing from a controlled trial.
Discussed as a tissue-repair peptide, naturally secreted by the thymus and more abundant in childhood, acting on stem cell proliferation and extracellular matrix formation. Frequently stacked with BPC-157.
His framing is similar and slightly cooler: substantial animal literature, minimal human clinical evidence, and a common misconception worth correcting — it is not a growth-promoting compound in the growth hormone sense.
This is the longest and most useful section of the solo episode, because he separates compounds that get lumped together. There are two mechanistic families.
Category 1 — GHRH analogues. These mimic growth hormone-releasing hormone and prompt the pituitary to release GH along something closer to its natural pulsatile rhythm.
Category 2 — GHRPs and ghrelin mimetics. These act on the ghrelin receptor, raising GH by a second route and suppressing somatostatin, the body's brake on GH release. More potent, and messier.
| Compound | Family | Huberman's stance |
|---|---|---|
| Sermorelin | GHRH | Discussed most favourably of the group. He has used it, and stopped — he reported it reduced his REM sleep |
| Tesamorelin | GHRH | Longer-acting; the one GHRH analogue with an actual approved indication (visceral fat reduction in HIV-associated lipodystrophy) |
| CJC-1295 | GHRH + DAC | Advises avoiding. Cites a death in a clinical trial and fluid retention; says use Sermorelin or Tesamorelin instead |
| Ipamorelin | GHRP | Relatively selective for the group, but drives hunger and may cost REM sleep |
| Hexarelin | GHRP | Advises strongly against, particularly at higher doses — sharp prolactin elevation and the risk of desensitising the receptor pathway |
| GHRP-2 / GHRP-6 family | GHRP | Flags raised cortisol and prolactin as class problems; evening cortisol elevation is the wrong thing at the wrong time |
| MK-677 | Oral ghrelin mimetic | Convenient, same cortisol and prolactin issues, same REM sleep concern |
Two structural warnings run underneath that table.
Receptor desensitisation. Continuous use without cycling can blunt the response, and in the case of hexarelin at high doses he describes the possibility of shutting the pathway down in a way that does not simply recover. The suggested pattern is roughly eight weeks on, eight to ten weeks off.
The REM sleep trade-off. Several of these increase slow-wave sleep while reducing REM. That reads as a win on a sleep tracker. Huberman's point is that REM is not optional — it does real work for emotional regulation and memory consolidation — so trading it for deep sleep is a trade, not an upgrade.
Worth separating what he says from the published record, because this claim travels. Huberman raises a death in a CJC-1295 trial linked to cardiovascular dysfunction, and treats it as reason enough to choose a different GHRH analogue.
The published human trial most often cited, Teichman and colleagues in JCEM (2006), reported adverse events that were mostly mild and local — injection site reactions, flushing — with no serious drug-related events in that dataset. Separately, the developer's clinical programme was discontinued after a participant death that was publicly characterised as unrelated to the study drug.
Both things can be true: a death occurred during development, its attribution was disputed, the programme stopped, and no long-term human safety data for CJC-1295 exists as a result. That last clause is the durable point.
One of his clearest positions, and one that is almost never clipped: if you are under 30, you are already producing plenty of growth hormone, and there is no physiological rationale for augmenting it absent a diagnosed clinical need.
He allows that the risk-benefit calculation shifts with age as endogenous production declines. He does not treat that shift as a green light — it moves the analysis, it does not conclude it.
Covered more briefly, and the pattern holds:
Both episodes land in the same place, and it is not a place that flatters the internet peptide market.
Huberman's repeated recommendation is to work with a board-certified physician and obtain material through a compounding pharmacy or a pharmaceutical supplier — explicitly not through grey-market channels. His stated concern is lipopolysaccharide (LPS) endotoxin contamination, which provokes an immune response, on top of the ordinary risks of mislabelling and inaccurate concentration.
Koniver, the physician guest, puts it more bluntly than Huberman does. He advises listeners against buying peptides sold online under research-use-only or not-for-human-consumption labelling, citing contamination risk including anaphylaxis, and argues the case for compounding pharmacies specifically because they are subject to pharmacy board oversight and do outside purity and endotoxin testing.
We supply research-grade peptides, and that advice still belongs in this article unedited. It is the single most consequential thing either of them says, and leaving it out to make the rest read better would be exactly the selective quoting this article is about. Research-grade purity is a chemical specification. It is not sterility, it is not endotoxin qualification, and it is not a pharmaceutical release standard. Anyone citing Huberman as a reason to buy should read what he actually recommends buying, and from whom.
Huberman speaks to a largely US audience, and his practical advice — get a prescription, use a compounding pharmacy — does not transfer cleanly.
In June 2024 Australia became the first country to add BPC-157 to Schedule 4 of the Poisons Standard, making it prescription-only. A range of other peptides discussed across these episodes sit in Schedule 4 as well. Importing a Schedule 4 substance without a prescription or a TGA pathway such as the Special Access Scheme is a regulatory breach, and customs seizure is the routine outcome. See our guide on research peptide legality in Australia for the detail.
So an Australian listener taking his advice literally is being pointed at a pathway that runs through a doctor here too — not around one.
Four recurring distortions, each of which reverses something he said:
1. "Huberman uses BPC-157." He described a specific past experience with a specific injury, in an episode devoted substantially to why the compound carries a theoretical cancer risk. A disclosure is not a protocol.
2. "Huberman recommends growth hormone peptides." He differentiates sharply between them, tells listeners to avoid at least two by name, and argues against use under 30 altogether.
3. Dosing numbers presented as his prescription. Figures discussed on the podcast are descriptions of what is done clinically, delivered alongside instructions to work with a physician. Stripping the second half changes what the first half means.
4. Silence on sourcing. The sourcing guidance is the most actionable content in both episodes and the least reproduced, because it points away from the channel most people buy through.
Does Andrew Huberman endorse or sell peptides?
No. He has no affiliation with this site or any product on it, and these episodes are educational content, not endorsements. Any vendor implying otherwise is misrepresenting him.
Does he say BPC-157 is safe?
No. He describes a plausible healing mechanism and a personal experience, alongside a theoretical cancer risk arising from that same mechanism, an absence of rigorous human trials, and contamination concerns in the unregulated market.
Which peptides does he explicitly warn against?
CJC-1295, on the basis of a trial death and fluid retention, and hexarelin, particularly at higher doses, on the basis of prolactin elevation and potential receptor desensitisation. He also raises cortisol and prolactin concerns across the GHRP family generally.
Has his position changed since 2024?
The two episodes are from April and October 2024 and remain the substantive treatments. Regulatory circumstances have moved considerably since — in both the US compounding review and Australian scheduling — but that is a change in the legal landscape, not in what he said about the biology.
Does the podcast give dosing protocols?
Dosing ranges are discussed, always in the context of physician supervision. This article deliberately omits them. Nothing here is a protocol, and reproducing numbers without the clinical framing they were given in is precisely the failure mode described above.
Disclaimer: This article summarises publicly available podcast content for educational purposes and is not medical advice. Andrew Huberman, PhD, and Craig Koniver, MD, are not affiliated with Peptide Labs, have not endorsed this site or any product on it, and are cited here solely as sources whose published statements are being reported. Quotations and positions are paraphrased summaries — consult the linked episodes directly for their exact wording. This article contains no dosing, route or administration guidance. All products supplied by Peptide Labs are sold strictly for in-vitro laboratory research and are not intended for human or veterinary use.
On 28 July 2026 the FDA released 17 revised draft product-specific guidances for generic peptide drugs — and withdrew the 2021 synthetic peptide guidance that underpinned the field. Here is what changed on impurities, higher order structure and immunogenicity testing.
ResearchSamsung Biologics' $1.8B bid for PolyPeptide is the latest in a wave of peptide capacity deals. Inside the GLP-1 demand shock, SPPS economics, purification bottlenecks and why CDMO capacity became a strategic asset.
99%+ HPLC purity · COA verified every batch · Next-day dispatch to Melbourne
Shop All Peptides